Consistent with the previous research, our data demonstrate that anti-PD-L1 mAb combined with 177Lu-EB-RGD, an integrin αvß3-targeted TRT, improve anti-tumor efficacy and prolong overall survival compared with either treatment alone. Here, CD274 is linked to neoplasm.